A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy.
Glioblastoma multiforme (GBM) is the most common primary brain tumor and among the most difficult to treat malignancies per se. In almost 90% of all GBM alterations in the PI3K/Akt/mTOR have been found, making this survival cascade a promising therapeutic target, particular for combination therapy t...
Main Authors: | Stephanie Ströbele, Matthias Schneider, Lukas Schneele, Markus D Siegelin, Lisa Nonnenmacher, Shaoxia Zhou, Georg Karpel-Massler, Mike-Andrew Westhoff, Marc-Eric Halatsch, Klaus-Michael Debatin |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4488267?pdf=render |
Similar Items
-
Temozolomide and Other Alkylating Agents in Glioblastoma Therapy
by: Hannah Strobel, et al.
Published: (2019-09-01) -
Therapeutic Drug-Induced Metabolic Reprogramming in Glioblastoma
by: Trang T. T. Nguyen, et al.
Published: (2022-09-01) -
Killing Me Softly—Future Challenges in Apoptosis Research
by: Mike-Andrew Westhoff, et al.
Published: (2014-03-01) -
PARP inhibition restores extrinsic apoptotic sensitivity in glioblastoma.
by: Georg Karpel-Massler, et al.
Published: (2014-01-01) -
Epigenetic Targeting of Mcl-1 Is Synthetically Lethal with Bcl-xL/Bcl-2 Inhibition in Model Systems of Glioblastoma
by: Enyuan Shang, et al.
Published: (2020-08-01)